Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Definium Therapeutics, Inc.DFTX · Entity 3884 | Chief Commercial Officer | September 14, 2026 | September 14, 2026 |
| Yarrow Bioscience, Inc.VYNE · Entity 6871 | Chief Commercial Officer | June 30, 2021 | July 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Definium Therapeutics, Inc.
Report date September 14, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 362,133 |
Reported balance
After 2026-09-14 transaction · row 1
1 source rowRow 1 · 2026-09-14 · Grant · Acquired 125,000 · Balance 362,133 F1: The common shares represent the third tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: The common shares represent the third tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.
Yarrow Bioscience, Inc.
Report date June 30, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 109,246 |
Reported balance
After 2021-06-30 transaction · row 1
1 source rowRow 1 · 2021-06-30 · Tax withholding · Disposed 5,151 · Balance 109,246 F1: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BioXcel Therapeutics, Inc.
Report date July 22, 2024 · Filed April 01, 2025
Section 16 reporting ended · disclosed 2025-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2034-07-22 | Direct | 1,875 |
Reported balance
After 2024-07-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-22 · Grant · Acquired 1,875 · Balance 1,875 F1: The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock. F2: The Reporting Person was granted an option to purchase 1,875 shares of common stock, which vests as to 50% on each of the first and second anniversaries of the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Due to the Reporting Person's termination of employment, the unvested Stock Option was forfeited. |
Filing footnotes · ownership attribution and instrument terms
F1: The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock.
F2: The Reporting Person was granted an option to purchase 1,875 shares of common stock, which vests as to 50% on each of the first and second anniversaries of the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Due to the Reporting Person's termination of employment, the unvested Stock Option was forfeited.
Foamix Pharmaceuticals Ltd.
Report date March 09, 2020 · Filed March 11, 2020
Section 16 reporting ended · disclosed 2020-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-03-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-03-09 · Disposition to issuer · Disposed 35,275 · Balance 78,799 F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. Row 2 · 2020-03-09 · Disposition to issuer · Disposed 78,799 · Balance 0 F3: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.06 · Expires 2028-12-03 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-03-09 · Disposition to issuer · Disposed 100,000 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F4: The ordinary shares underlying this option vest over a period of four years (25% on December 31, 2019 and 6.25% every three months thereafter) ending December 31, 2022. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.03 · Expires 2030-02-24 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-03-09 · Disposition to issuer · Disposed 96,365 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F6: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2)
F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement.
F3: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR.
F4: The ordinary shares underlying this option vest over a period of four years (25% on December 31, 2019 and 6.25% every three months thereafter) ending December 31, 2022.
F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options.
F6: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 14, 2026 12:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-389890 · ownership.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,133 F1 · shares: The common shares represent the third tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. Read SEC document |
| August 12, 2026 Filed Aug 12, 2026 12:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-345836 · ownership.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,133 F1 · shares: The common shares represent the second tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 20:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | SaleCommon Shares | 2,867 | $45.03 | $129,101.01 |
DisclosureSEC source: 0001193125-26-285558 · ownership.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,633 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on May 29, 2025. Read SEC document |
| June 22, 2026 Filed Jun 22, 2026 13:45 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-276881 · ownership.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,500 F1 · shares: The common shares represent the first tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 22:00 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 115,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-039598 · ownership.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 20:45 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0000950170-25-041302 · ownership.xml · derivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Shares · 350,000 shares Expires 2035-03-16 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 01:55 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 6,272 | $0.55 | $3,449.60 |
DisclosureSEC source: 0001104659-24-106064 · tm2425607-7_4seq1.xml · nonDerivative · entry 2 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,011 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Read SEC document |
| September 17, 2024 Filed Oct 4, 2024 01:55 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantCommon Stock | 21,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-106064 · tm2425607-7_4seq1.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,283 F1 · price: The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through October 1, 2024 (the "PSUs"). On September 17, 2024, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 21,250 PSUs had been satisfied and 21,250 shares of common stock became issuable to the Reporting Person on October 1, 2024. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:18 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 215 | $0.69 | $148.52 |
DisclosureSEC source: 0001104659-24-100746 · tm2424255-5_4seq1.xml · nonDerivative · entry 2 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,033 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 23:18 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-100746 · tm2424255-5_4seq1.xml · derivative · entry 3 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 23:18 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100746 · tm2424255-5_4seq1.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| July 22, 2024 Filed Apr 1, 2025 22:06 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (right to buy) · Derivative | 1,875 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001104659-25-030684 · tm2511097-4_4seq1.xml · derivative · entry 1 Wiley Matthew T. · CIK 0001759703 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires 2034-07-22 F1 · shares: The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock. F2 · derivative.exercise_date: The Reporting Person was granted an option to purchase 1,875 shares of common stock, which vests as to 50% on each of the first and second anniversaries of the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Due to the Reporting Person's termination of employment, the unvested Stock Option was forfeited. Read SEC document |
| June 17, 2024 Filed Jun 19, 2024 01:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 244 | $1.26 | $308.10 |
DisclosureSEC source: 0001104659-24-073003 · tm2417544-6_4seq1.xml · nonDerivative · entry 2 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,498 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Read SEC document |
| June 15, 2024 Filed Jun 19, 2024 01:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073003 · tm2417544-6_4seq1.xml · derivative · entry 3 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,250 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 15, 2024 Filed Jun 19, 2024 01:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-073003 · tm2417544-6_4seq1.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 15, 2024 Filed Sep 17, 2024 23:17 UTC Amendment | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-100745 · tm2424255-4_4aseq1.xml · derivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,250 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 23:31 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 1,008 | $2.64 | $2,656.18 |
DisclosureSEC source: 0001104659-24-044859 · tm2411220-3_4seq1.xml · nonDerivative · entry 2 Wiley Matthew T. · CIK 0001759703 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,992 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $2.62 to $2.6502. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Apr 8, 2024 23:31 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-044859 · tm2411220-3_4seq1.xml · derivative · entry 3 Wiley Matthew T. · CIK 0001759703 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F4 · derivative.expiration_date: The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 15, 2024 Filed Apr 8, 2024 23:31 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 3,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-044859 · tm2411220-3_4seq1.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 21:58 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $19.60 | $0.00 |
DisclosureSEC source: 0001104659-23-033401 · tm239796-2_4seq1.xml · derivative · entry 2 Wiley Matthew T. · CIK 0001759703 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2033-03-15 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 15, 2023 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 21:58 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-033401 · tm239796-2_4seq1.xml · derivative · entry 1 Wiley Matthew T. · CIK 0001759703 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| January 17, 2022 Filed Jan 19, 2022 21:19 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001104659-22-005451 · tm223835-2_4seq1.xml · derivative · entry 1 Wiley Matthew T. · CIK 0001759703 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2032-01-16 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of January 17, 2022 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:36 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 5,151 | $3.51 | $18,080.01 |
DisclosureSEC source: 0001209191-21-044980 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,246 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 16:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 2,573 | $6.84 | $17,599.32 |
DisclosureSEC source: 0001209191-21-024412 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,397 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:40 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 64,575 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001209191-21-013821 · doc4.xml · derivative · entry 2 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,575 Underlying: Common Stock · 64,575 shares Expires 2031-02-22 F2 · derivative.exercise_date: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:40 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 27,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013821 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,970 F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. F2 · shares: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:32 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 1,541 | $1.58 | $2,434.78 |
DisclosureSEC source: 0001209191-21-001097 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,181 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:31 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 7,838 | $1.45 | $11,325.91 |
DisclosureSEC source: 0001209191-20-061177 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,722 F1 · shares: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on April 1, 2020 and ending on November 30, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on November 30, 2020 (the last trading day of the offering period). The reporting person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 20:32 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 1,541 | $1.66 | $2,558.06 |
DisclosureSEC source: 0001209191-20-053159 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,884 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:25 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Tax withholdingCommon Stock | 1,541 | $1.73 | $2,665.93 |
DisclosureSEC source: 0001209191-20-040308 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,425 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:54 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 150,000 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001209191-20-028039 · doc4.xml · derivative · entry 2 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-05-06 F2 · derivative.exercise_date: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:54 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-028039 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,967 F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo Therapeutics Inc. F2 · shares: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 21:23 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Tax withholdingCommon Stock | 908 | $1.40 | $1,271.20 |
DisclosureSEC source: 0001209191-20-023813 · doc4.xml · nonDerivative · entry 3 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,967 F4 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:23 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 91,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023813 · doc4.xml · nonDerivative · entry 2 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,875 F3 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo. F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) F2 · price: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:23 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 46,394 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023813 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,445 F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) F2 · price: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:41 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Tax withholdingCommon Stock | 525 | $2.68 | $1,407.00 |
DisclosureSEC source: 0001209191-20-022591 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,051 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:57 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 57,086 | Not disclosed Strike: $6.81 | Not disclosed |
DisclosureSEC source: 0001209191-20-018229 · doc4.xml · derivative · entry 4 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,086 Underlying: Common Stock · 57,086 shares Expires 2030-02-24 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. F4 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:57 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 59,240 | Not disclosed Strike: $6.86 | Not disclosed |
DisclosureSEC source: 0001209191-20-018229 · doc4.xml · derivative · entry 3 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,240 Underlying: Common Stock · 59,240 shares Expires 2028-12-03 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. F3 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on December 31, 2019 and 6.25% every three months thereafter) ending December 31, 2022. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:57 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 46,680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018229 · doc4.xml · nonDerivative · entry 2 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,576 F2 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo. F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:57 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 20,896 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018229 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,896 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:41 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 96,365 | Not disclosed Strike: $4.03 | Not disclosed |
DisclosureSEC source: 0001209191-20-018204 · doc4.xml · derivative · entry 4 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 96,365 shares Expires 2030-02-24 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F6 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:41 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 100,000 | Not disclosed Strike: $4.06 | Not disclosed |
DisclosureSEC source: 0001209191-20-018204 · doc4.xml · derivative · entry 3 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 100,000 shares Expires 2028-12-03 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F4 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on December 31, 2019 and 6.25% every three months thereafter) ending December 31, 2022. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:41 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOrdinary Shares | 78,799 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018204 · doc4.xml · nonDerivative · entry 2 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:41 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOrdinary Shares | 35,275 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018204 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,799 F1 · price: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2 · price: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 16:39 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOrdinary Shares | 1,993 | $2.68 | $5,336.26 |
DisclosureSEC source: 0001209191-20-015241 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,074 F1 · kind: These shares were acquired under the Foamix Pharmaceuticals Ltd. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2019 and ending on March 2, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on December 2, 2019 (the first trading day of the offering period). Read SEC document |
| February 24, 2020 Filed Feb 24, 2020 18:39 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOptions · Derivative | 96,365 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-20-012200 · doc4.xml · derivative · entry 2 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,365 Underlying: Ordinary Shares · 96,365 shares Expires 2030-02-24 F3 · security: Each option represents a contingent right to purchase one ordinary share of the issuer. F4 · derivative.exercise_date: The ordinary shares underlying these options vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024. Read SEC document |
| February 24, 2020 Filed Feb 24, 2020 18:39 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOrdinary Shares | 41,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-012200 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,081 F1 · security: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F2 · shares: The ordinary shares underlying this restricted share unit award vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 17:24 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Tax withholdingOrdinary Shares | 2,500 | $3.28 | $8,200.00 |
DisclosureSEC source: 0001209191-20-001250 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,782 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of the restricted share units and does not represent a sale by the Reporting Person. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 16:31 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOrdinary Shares | 9,842 | $2.16 | $21,248.88 |
DisclosureSEC source: 0001209191-19-058712 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,282 F1 · kind: These shares were acquired under the Foamix Pharmaceuticals Ltd. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on June 1, 2019 and ending on December 1, 2019 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on June 3, 2019 (the first trading day of the offering period). The reporting person purchased the maximum number of shares permitted by the terms of the ESPP during the offering period. Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 16:07 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | PurchaseOrdinary Shares | 13,440 | $3.76 | $50,534.40 |
DisclosureSEC source: 0001209191-19-017304 · doc4.xml · nonDerivative · entry 1 Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,440 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.725 to $3.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.